As expected, after 18 h of treatments, 5 μM dose of Rimonabant failed to reduce CD133+/CD44+ cells, while 10, 15, and 20 μM doses significantly reduce them, in both differentiated tumor cells and CSCs (Figures 4A,B). The gene discussed is PROM1; the disease is neoplasm.